Dnavec Corporation
Records under this name other than the patents Dnavec Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 8 of 8 · Back to Dnavec Corporation
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,695,445 | Method for production of reprogrammed cell using chromosomally unintegrated virus vector Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,136,594 | Method for production of reprogrammed cell using chromosomally unintegrated virus vector Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,447,432 | Method for Producing Induced Pluripotent Stem Cells Formerly held In force · High confidence | In force | High confidence | |
| US 9,492,485 | Pluripotent stem cell-derived brown adipocytes, pluripotent stem cell-derived cell aggregate, method for producing same, and cell therapy and medical therapy therefor Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,127,256 | Method for production of reprogrammed cell using chromosomally unintegrated virus vector Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,741,639 | Method for producing dendritic cells Lapsed on the fee record Ended Jun 3, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jun 3, 2022 | From the USPTO record |
| US 8,283,163 | Method for production of dendritic cell Lapsed on the fee record Ended Oct 9, 2020 · From the USPTO record | Lapsed on the fee record | Ended Oct 9, 2020 | From the USPTO record |
| US 8,278,284 | Therapeutic Agents for Diseases Associated with Apoptotic Degeneration in Ocular Tissue Cells That Use Siv-Pedf Vectors Formerly held Lapsed on the fee record Ended Oct 2, 2020 · High confidence | Lapsed on the fee record | Ended Oct 2, 2020 | High confidence |